GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted therapy combo aims to fight stubborn stomach cancers
Disease control Recruiting nowThis Phase 3 trial is testing whether a new targeted drug called sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly an immunotherapy (rilvegostomig), can help people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specifi…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New drug combo aims to shrink hard-to-treat gut tumors
Disease control Recruiting nowThis study tests a new drug called DR30206 combined with standard treatments for people with advanced or spreading gastrointestinal cancers, like colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. About 186 adults in China will take part.
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New cancer drug YL211 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could diabetes pills boost cancer immunotherapy?
Disease control Recruiting nowThis phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New biologic TRK-950 joins forces with standard chemo to fight stomach cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental biologic called TRK-950 to the standard combination of ramucirumab and paclitaxel helps people with advanced stomach or gastroesophageal junction cancer. Participants receive either the standard two-drug regimen or the stand…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat cancers: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill combo aims to shrink Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for stomach cancer: targeted drug combo enters final testing
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug combination (tecotabart vedotin plus tislelizumab) works better than standard chemotherapy for people with advanced stomach cancer that has a specific protein called CLDN18.2. The study plans to enroll 752 participants who have not…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Stomach cancer patients may soon get immunotherapy as a simple shot instead of an IV drip
Disease control Recruiting nowThis phase 3 trial compares a subcutaneous (under-the-skin) injection of tislelizumab to the standard intravenous (IV) infusion, both given with chemotherapy, as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has sp…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Targeted chemotherapy infusion aims to control advanced stomach cancer
Disease control Recruiting nowThis phase 2 trial tests whether delivering FOLFOX chemotherapy directly into the arteries feeding the tumor can help control advanced stomach or gastroesophageal junction cancer. The study includes 31 adults who cannot have surgery due to frailty or other health issues. The main…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Chemotherapy directly into the belly: a new hope for advanced stomach cancer?
Disease control Recruiting nowThis study tests whether giving the chemotherapy drug paclitaxel directly into the abdominal cavity, along with standard intravenous chemo, can help people with stomach cancer that has spread to the lining of the abdomen. About 148 adults with this condition will be randomly assi…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of drugs could shrink stomach tumors before surgery
Disease control Recruiting nowThis study tests several new drug combinations given before and after surgery for stomach or esophageal cancer. About 100 people with resectable tumors will receive these treatments to see if they are safe and can shrink or eliminate the cancer. The goal is to improve outcomes by…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for stomach cancer: phase 3 trial tests rilvegostomig combo
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug called rilvegostomig, combined with trastuzumab deruxtecan and chemotherapy, works better than the current standard treatment for HER2-positive stomach cancer that has spread. About 840 people whose tumors have a specific protein (…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug BAL0891 enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer cocktail enters human testing
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug CT-95 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a common supplement boost cancer therapy? new trial tests taurine with immunotherapy for stomach cancer.
Disease control Recruiting nowThis study tests whether adding the supplement taurine to a standard treatment (immunotherapy drug serplulimab plus chemotherapy) can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 96 adults whose tumors have a specific marker…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to extend life in tough stomach cancer
Disease control Recruiting nowThis Phase 3 trial tests a new drug called BL-M05D1 against standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). The study will include 438 adults who have already tried one prior treatment. The goal is …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo aims to wipe out stomach cancer before surgery
Disease control Recruiting nowThis study tests whether adding a new drug called IBI343 to standard immunotherapy and chemotherapy can help eliminate stomach cancer more effectively before and after surgery. It involves 90 adults with a specific type of stomach cancer that has not spread widely. Participants w…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental virus and CAR t combo takes on Hard-to-Treat GI cancers
Disease control Recruiting nowThis early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study ai…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Dispatch Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Triple threat: immunotherapy and targeted drug join chemo to fight HER2+ gut cancers
Disease control Recruiting nowThis phase 2 study is testing whether adding two newer drugs—pembrolizumab (an immunotherapy) and trastuzumab (a targeted therapy)—to standard chemotherapy can help people with HER2-positive esophageal or stomach cancer that can be surgically removed. About 49 adults will receive…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for stomach cancer: experimental drug combo trial opens
Disease control Recruiting nowThis study tests new experimental drugs combined with standard chemotherapy and immunotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the combination to …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo shows promise for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New targeted therapy aims to extend life in stomach cancer
Disease control Recruiting nowThis Phase 3 trial tests a new drug, SHR-A1904, in 524 people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). Participants receive either SHR-A1904 or standard chemotherapy. The main goal is to see if the new drug helps people liv…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called LBL-024 combined with other cancer drugs (capecitabine, tislelizumab, and oxaliplatin) in 110 adults with advanced solid tumors. The goal is to see if the combination shrinks tumors and is safe. Participants must be in good overall hea…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for advanced stomach cancer: experimental drug combos enter human trials
Disease control Recruiting nowThis study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for stomach cancer: drug combo aims to outperform chemo
Disease control Recruiting nowThis study tests a new combination of drugs (LM-108 and toripalimab) against standard chemotherapy for people with advanced stomach cancer that has gotten worse after first treatment. About 400 adults with a specific marker (CCR8-positive) will be randomly assigned to receive eit…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug sigvotatug vedotin enters human trials
Disease control Recruiting nowThis early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for advanced cancer patients as experimental drug enters human testing.
Disease control Recruiting nowThis early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
When to treat? new trial aims to optimize therapy for oligometastatic esophageal and gastric cancer
Disease control Recruiting nowThis clinical trial is looking at the best timing for local treatments like surgery or radiation in people with esophageal or stomach cancer that has spread to only a few spots. All participants first get 4 months of standard drug therapy. Then, depending on their response, they …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental drug duo targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug IBI343 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug candidate BL-M05D1 enters early human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Cancer-Killing virus combined with keytruda shows promise in stubborn tumors
Disease control Recruiting nowThis phase 2 study tests a new approach for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is either PD-L1-negative or has stopped responding to immunotherapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into th…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for stomach cancer: experimental drug combo targets tough tumors
Disease control Recruiting nowThis study tests a new drug called ATG-022 combined with the immunotherapy pembrolizumab (Keytruda), with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and is HER2-negative. The trial aims to fin…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New Two-Part cancer drug enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Tagworks Pharmaceuticals BV • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental nanoparticle boosts radiation against esophageal cancer
Disease control Recruiting nowThis early-phase trial tests a new drug called NBTXR3, which is injected into the tumor and activated by radiation to destroy cancer cells. It is given alongside standard chemotherapy for people with stage II–III esophageal adenocarcinoma. The main goals are to find the safest do…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Robotic surgery and heated chemo could be a Game-Changer for stomach cancer patients
Disease control Recruiting nowThis study tests a new way to treat stomach cancer that has spread to the lining of the belly. Doctors will use a robot to remove visible cancer and then deliver heated chemotherapy directly into the abdomen during surgery. The goal is to help patients recover faster and have few…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New smart drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to shrink stomach tumors in Mid-Stage trial
Disease control Recruiting nowThis Phase 2 study tests a new drug, telisotuzumab adizutecan (ABBV-400), combined with standard chemotherapy and an immunotherapy drug for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will recei…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising drug combo aims to stop stomach cancer in its tracks
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) can help prevent stomach or gastroesophageal junction cancer from coming back after surgery. It includes 276 adults with high-risk or specific genetic types of cancer. Participants ar…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to boost immune attack on stomach cancer
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (thymosin alpha 1) to standard chemo-immunotherapy can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 participants will receive either the standard treatment or the standard plus thymos…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug duo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for stomach cancer: targeted drug combo under study
Disease control Recruiting nowThis study is testing a drug called zolbetuximab combined with standard chemotherapy in people with a specific type of advanced stomach cancer that has spread. The cancer must have a protein called claudin 18.2 on at least 75% of its cells and be HER2-negative. The goal is to see…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: European Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for stomach cancer: experimental combo enters final trial phase
Disease control Recruiting nowThis phase 3 trial is testing whether a new combination of drugs (SHR-A1811, adebrelimab, and chemotherapy) works better than the current standard treatment for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The study will enrol…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for stomach cancer: Real-World study explores better Second-Line treatments
Disease control Recruiting nowThis study looks at different drug combinations for people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. Researchers will observe 250 participants receiving albumin-bound paclitaxel-based regimens, including immune check…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug KK2269 enters first human tests
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy aims to boost immune attack on hard-to-treat GI cancers
Disease control Recruiting nowThis study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Triple threat: new Pre-Surgery combo targets stomach cancer
Disease control Recruiting nowThis study is testing whether giving a shorter course of radiation (hypofractionated radiotherapy) along with immunotherapy (serplulimab) and chemotherapy before surgery can safely improve outcomes for people with gastroesophageal junction cancer. The trial will enroll 84 partici…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Triple-Drug cocktail aims to extend life in tough stomach cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding two drugs (adebrelimab and famitinib) to standard chemotherapy (irinotecan) can help people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. About 66 participants will be randomly assigned to …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shandong Tumor Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for stomach cancer patients who failed first treatment
Disease control Recruiting nowThis study tests a combination of three drugs (SHR-1701, rivoceranib, and possibly SHR-2554) in 40 adults with advanced stomach or gastroesophageal junction cancer that worsened after or could not tolerate first-line immunotherapy. The goal is to see if the new combo can shrink t…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jingdong Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New antibody TST001 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called TST001, an antibody that targets a protein called Claudin18.2 found on some cancer cells. It is given alone or with chemotherapy to people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo therapy aims to shrink hard-to-treat stomach cancer before surgery
Disease control Recruiting nowThis study tests a new approach for people with advanced gastroesophageal junction cancer that cannot be removed with surgery right away. The treatment combines targeted radiation, immunotherapy, and chemotherapy to shrink the tumor enough for surgery. The goal is to see if this …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for stomach cancer: targeted drug BL-M07D1 enters final trial
Disease control Recruiting nowThis phase 3 trial tests a new drug called BL-M07D1 against standard chemotherapy in 490 people with HER2-positive advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. The study aims to see if BL-M07D1 helps people live longer or slows c…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug duo offers hope for advanced stomach cancer patients
Disease control Recruiting nowThis study tests two experimental drugs, AK109 and AK104, with or without chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. The goal is to see if the combination can shrink tumors or slow disease pro…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug cocktail aims to wipe out hard-to-treat stomach cancer before surgery
Disease control Recruiting nowThis study tests whether adding a new drug (liposomal irinotecan) to standard chemotherapy before chemoradiation can completely eliminate cancer in people with advanced gastroesophageal cancer. About 40 adults with stage T3/4 or node-positive disease will receive the combination,…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take on stomach cancer in Late-Stage trial
Disease control Recruiting nowThis phase 3 trial tests a new treatment called IMC002, which uses a patient's own immune cells (CAR T-cells) engineered to target a protein called CLDN18.2 found on some stomach cancer cells. The study includes 150 adults with advanced stomach cancer that has not responded to at…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a common ED drug boost chemo for stomach cancer?
Disease control Recruiting nowThis study tests whether adding tadalafil (a drug used for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. Ten adults with resectable cancer will receive tadalafil alone for two weeks, then combined with c…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New smart drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cord blood cells take on stomach cancer: new hope in Late-Stage trial
Disease control Recruiting nowThis study tests a new treatment called RAK cell therapy, made from human umbilical cord blood, for people with advanced stomach cancer that has spread or come back after standard treatment. The goal is to see if it can help patients live longer and keep the cancer from growing, …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Engineered immune cells take on stomach cancer in new trial
Disease control Recruiting nowThis phase 1b trial is testing a personalized cell therapy called CT041 CAR-T for people with advanced stomach or gastroesophageal junction cancer. After completing standard first-line treatment, 20 participants will receive up to three infusions of their own engineered immune ce…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Genetic cheat code may unlock safer, stronger chemo cocktail for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a powerful mix of five chemotherapy drugs for people with advanced upper gastrointestinal cancers, including pancreatic and stomach cancers. The study uses each person's genetic profile to adjust the dose of one of the drugs (irinotecan) to try t…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New cocktail aims to turn inoperable stomach cancer into operable tumors
Disease control Recruiting nowThis study tests whether a combination of three drugs (RC48, sintilimab, and SOX) can shrink advanced stomach cancer enough to allow surgical removal. It includes 30 adults with a specific type of HER2-positive cancer who have not had prior treatment. The goal is to see how many …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug cocktail targets Hard-to-Treat stomach cancer
Disease control Recruiting nowThis Phase 2 trial is testing whether a new targeted drug called SHR2554, taken as a tablet, can be safely combined with other anti-cancer injections to treat advanced stomach or gastroesophageal junction cancer. The study will enroll 351 adults whose cancer has spread or cannot …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:42 UTC
-
Cancer patients may soon get immunotherapy at home instead of the clinic
Symptom relief Recruiting nowThis study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Which stomach cancer surgery is easier on patients? new study aims to find out
Symptom relief Recruiting nowThis study compares symptoms, especially appetite, in patients who have one of two types of minimally invasive stomach cancer surgery: removing only the upper part of the stomach or the whole stomach. Researchers will track how patients feel using a simple questionnaire. The goal…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New registry aims to find best treatments for Limited-Stage esophageal cancer
Knowledge-focused Recruiting nowThis study is creating a database to track how people with esophageal or gastroesophageal junction cancer that has spread to only a few places (like the liver or lymph nodes) are treated in real-world settings. Researchers will collect information from 50 participants to see whic…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Blood test may predict stomach cancer comeback before scans do
Knowledge-focused Recruiting nowThis study is testing whether a personalized blood test that looks for tumor DNA can detect stomach cancer recurrence earlier than standard imaging. About 110 patients who had chemotherapy and surgery for stage II-III stomach cancer will give blood samples over time. The goal is …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Peking University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Blood test could revolutionize stomach cancer treatment monitoring
Knowledge-focused Recruiting nowThis study looks at whether a blood test that detects tumor DNA (ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. About 600 participants will provide blood samples before and during treatment to see if changes in ctDNA levels predict re…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Scientists probe genetic changes when GI cancers spread to brain
Knowledge-focused Recruiting nowThis study looks at tissue samples from 30 adults with stomach or esophageal cancer that spread to the brain. Researchers compare the genetic markers of the original tumor and the brain tumor to see if they differ. The goal is to better understand how these cancers change when th…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Massive german registry to map real-world cancer care for 1,900 patients
Knowledge-focused Recruiting nowThis study is a large registry that will collect information from about 1,900 people with advanced cancer of the esophagus or stomach who are receiving palliative treatment in Germany. The goal is to understand what treatments are actually used in everyday practice and how patien…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Can Lab-Tested tumor fragments pick the right drug for stubborn cancers?
Knowledge-focused Recruiting nowThis study tests a new method to help choose cancer drugs for people with hard-to-treat solid tumors. Doctors take a small piece of the tumor, grow it in the lab, and test many drugs on it to see which works best. Then they give that drug to the patient. The goal is to see if thi…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC